Metatron Intelligence
Today: the five AI headlines of the day → and the AI Wiki
What a domain is How to read this page

One of twenty-four connected subject areas

Domains are how claims relate to one another inside the Atlas. Desks are how readers find them. A claim can sit in more than one domain without being counted twice.

Coverage here is not importance

A domain with more claims has been worked on more, which is a fact about this publication rather than a fact about the world.

Everything returns to the record

Each entry links to its canonical claim record, with its source, its non-claim and its update condition intact.

New to this publication?

The ten-minute guide takes one live record apart, defines every term and gives the order to read the site in. Start here →

Business · D04

Health, Evidence, Supplements & Peptides

446 connected claims · 355 source-domain links · Priority P0

Search and filter this domain →
  1. MWITA-CR-2026-0005Consumer-Wearables liefern häufig Screening- oder Triage-Signale, sind aber ohne getrennten Nachweis analytischer Validität, klinischer Validität und klinischen Nutzens keine Diagnosen.Evidence B · P0
  2. MWITA-CR-2026-0006Änderungen von NAD-Verfügbarkeits- oder biologischen Altersmarkern belegen für sich weder mehr Funktion noch längere menschliche Lebensspanne.Evidence B · P0
  3. MWITA-CR-2026-0007Ein Reinheitswert oder COA allein belegt bei Peptiden weder korrekte Identität und Potenz noch Sterilität, Stabilität oder chargenrepräsentative Sicherheit.Evidence A · P0
  4. MWITA-CR-2026-0008Metatron sollte Health-Aussagen als versionierte, juristiktions- und populationsgebundene Claims führen und AI auf Suche, Extraktion und Widerspruchserkennung begrenzen, während medizinische Schlussfolgerung und Freigabe unter fachlicher menschlicher Autorität bleiben.Evidence B · P0
  5. MWITA-CR-2026-0031EHDS wird zwischen 2027 und 2035 stufenweise grenzüberschreitende Gesundheitsdaten- und RWE-Infrastruktur erweitern; 2026 ist eine pauschale EHDS-compliant-Aussage eher Readiness als Zertifizierung.Evidence A · P1
  6. MWITA-KI-2026-011Statistics Korea's medium projection estimates the population aged 65 and over will reach 47.7% in 2072, from 17.4% in 2022.Evidence A · P1
  7. MWITA-KI-2026-019ABDM describes a federated architecture in which health records remain with their providers and are exchanged securely with patient consent; central services hold registries rather than a national record lake.Evidence A · P0
  8. MWITA-KI-2026-020A May 2026 Government of India release reported more than 100 crore health records linked under ABDM, up from 50 crore over 15 months.Evidence B · P1
  9. MWITA-AP-2026-008Indonesia requires all enumerated healthcare facilities to integrate with SATUSEHAT under Health Minister Regulation 24/2022, while the platform specifies HL7 FHIR, HTTPS REST APIs, authentication and encryption rather than replacing every local application.Evidence A · P1
  10. MWITA-AP-2026-011Vietnam's Decree 102/2025, effective 2025-07-01, regulates 24 health-data fields, a national health database, access and consent, and linkage of lawful health facilities to electronic health records integrated with national electronic identity.Evidence A · P1
  11. MWITA-AP-2026-012Vietnam's Health Ministry reported that only 153 of roughly 1,500 healthcare facilities had declared successful paperless EMR deployment in early April 2025, despite a national target for all hospitals by September 2025.Evidence B · P1
  12. MWITA-AF-2026-013Kenya's Ministry of Health reported on 13 January 2025 that 17.8 million people had registered with the Social Health Authority and 8,500 facilities had enrolled on its provider portal, with 87% of those facilities having logged in.Evidence B · P0
  13. MWITA-AF-2026-014SAHPRA published version 1 of MD08-2025/2026 on 19 August 2025, setting regulatory requirements for AI/ML-enabled medical devices in South Africa.Evidence A · P0
  14. MWITA-AF-2026-015WHO Africa's 2025 annual report says more than 1,500 health facilities in Ethiopia, Uganda, and Zambia were solar-electrified, benefiting an estimated 13 million people.Evidence B · P1
  15. MWITA-FT-2026-001A customized lipid-nanoparticle CRISPR base-editing therapy was designed, authorized and administered to one infant with CPS1 deficiency within roughly six months; the patient tolerated two infusions and showed improved protein tolerance and reduced ammonia-control medication.Evidence B · P1
  16. MWITA-FT-2026-002A four-year evaluation of cluster-randomized RTS,S introduction in Ghana, Kenya and Malawi associated routine vaccine introduction with about one in eight child deaths averted among eligible children.Evidence A · P1
  17. MWITA-FT-2026-003In the prospective randomized MASAI study, AI-supported mammography screening detected more cancers and reduced screen-reading workload by 44.2% without a statistically significant increase in false positives in the reported secondary analysis.Evidence A · P1
  18. MWITA-FT-2026-004Rentosertib, whose target and molecule were described as generated through AI methods, completed a multicentre randomized placebo-controlled phase 2a trial in China; the primary endpoint was safety and tolerability, while lung-function findings were exploratory.Evidence B · P1
  19. MWITA-FT-2026-005Anvisa registered the Butantan dengue vaccine in December 2025 for ages 12–59 after a five-year Brazilian phase 3 programme; regulatory approval and local production capability now precede national rollout evidence.Evidence A · P1
  20. MWITA-ME-2026-019Abu Dhabi Department of Health's 2025 Responsible AI Standard sets minimum lifecycle requirements for DoH and all licensed healthcare entities developing, procuring or deploying AI across clinical, financial, administrative and related functions.Evidence A · P0
  21. MWITA-ME-2026-020Saudi Arabia's Health Sector Transformation Program reported for 2025 that the Sehhaty application exceeded 31 million beneficiaries and the virtual hospital served more than 365,000 beneficiaries through 241 connected facilities.Evidence B · P1
  22. MWITA-ME-2026-023Dubai's 2025 State of AI Report assessed more than 100 high-impact government AI use cases that were deployed or in development across urban planning, health, mobility, finance, procurement, hiring, compliance and decision support.Evidence B · P1
  23. MWITA-WD-2026-007FDA's January 2025 draft guidance proposes lifecycle and marketing-submission recommendations for AI-enabled device software, while expressly remaining draft, non-binding and not for implementation.Evidence A · P0
  24. MWITA-WD-2026-012Federal, provincial and territorial health governments except Quebec endorsed Pan-Canadian AI for Health guiding principles published in January 2025, covering privacy/security, lifecycle safety, accountability, transparency and AI literacy.Evidence A · P1
  25. MWITA-MB-2026-020A 2025 randomized surgical-simulation trial found expert instructors augmented with AI performance data produced better skill acquisition and transfer than an intelligent tutor condition.Evidence A · P1
  26. MWITA-MB-2026-021In a 16-facility cluster-randomized trial with 9,691 patients, generative-AI decision support did not significantly reduce the prespecified 14-day treatment-failure composite; rare patient outcomes required far larger samples.Evidence A · P1
  27. MWITA-MB-2026-022FDA's 2025 request for comment states that retrospective tests and static benchmarks provide a baseline but are not designed to predict dynamic real-world behavior, motivating ongoing monitoring for drift and performance variation.Evidence A · P1
  28. MWITA-MB-2026-023CONSORT 2025 and SPIRIT 2025 specify minimum reporting for randomized trials; AI extensions require algorithm version, inputs, outputs, error handling and human-AI interaction to be described.Evidence A · P1
  29. MWITA-CI-2026-019Brazil's Nova Industria Brasil programme page states an expected R$300 billion programme envelope through 2026 and a 2033 mission target to cut industrial CO2 intensity per value added by 30%; these are finance architecture and policy targets, not disbursement or achieved reductions.Evidence A · P1
  30. MWITA-CI-2026-023South Africa's environment deputy minister stated in January 2025 that the country generated more than 360,000 tonnes of e-waste annually and properly recycled only about 10%; 2023 externally audited EPR reports recorded R158 million in sector fees.Evidence B · P0
  31. MWITA-CI-2026-027UNIDO's 2025 policy research treats diversification, regional integration, resource efficiency and transparent trade frameworks as resilience mechanisms, but does not establish a universal firm-level outcome from any single intervention.Evidence A · P1
  32. MWITA-CI-2026-029South Africa's gazetted December 2025 National Waste Management Strategy 2026 document was explicitly a fourth draft; its proposed diversion and EPR targets are consultation-stage policy, not final rules or achieved circularity outcomes.Evidence A · P2
  33. MWITA-FAW-2026-001SOFI 2025 estimated that 673.2 million people, 8.2% of the global population, were undernourished in 2024, down from 688.4 million and 8.5% in 2023.Evidence A · P0
  34. MWITA-FAW-2026-002SOFI 2025 estimated 306.5 million undernourished people in Africa in 2024, up from 296.2 million in 2023, while Asia and South America drove the modest global improvement.Evidence A · P0
  35. MWITA-FAW-2026-003FAO's SOFI 2026 launch reported an estimated 645 million people facing hunger in 2025, 7.8% of the global population and about 14 million fewer than in 2024.Evidence A · P0
  36. MWITA-FAW-2026-004SOFI 2026 reported Africa's hunger prevalence easing from 20.3% in 2024 to 20.0% in 2025 while approximately 309 million people remained undernourished, showing that a lower rate need not mean a lower absolute count.Evidence A · P0
  37. MWITA-FAW-2026-005AfDB's 2026 effectiveness review reported Africa's cereal yield at 1.68 tonnes per hectare in 2024, broadly unchanged from 1.69 in 2020 and below the cited global average of about 4.2.Evidence A · P0
  38. MWITA-FAW-2026-006AfDB's 2025 portfolio reporting says 6.9 million farmers adopted climate-resilient technologies; this is Bank-reported reach/adoption, not evidence of persistence, income gains or climate-loss reduction.Evidence B · P1
  39. MWITA-FAW-2026-007AfDB reported Zimbabwe's completed emergency food-production project's Seed Revolving Fund supported more than 90,957 farmers, including about 33,108 women, and recorded loan repayment above 90% by June 2026.Evidence B · P1
  40. MWITA-FAW-2026-008World Bank project monitoring reported beneficiary sales in The Gambia increased 78% from project start and more than 53,000 farmers adopted climate-smart practices in 2025.Evidence B · P1
  41. MWITA-FAW-2026-009World Bank reporting says more than 835,000 farmers and breeders in Senegal gained index-based insurance coverage against drought and rainfall shocks in 2025.Evidence B · P1
  42. MWITA-FAW-2026-010The World Bank reported Nigeria's TRIMING project modernized 43,400 hectares and described output as sufficient to feed one million people; the latter is a food-equivalent estimate rather than counted beneficiaries consuming project crops.Evidence B · P1
  43. MWITA-FAW-2026-027South Africa's audited 2024/25 environment report recorded 158 previously disadvantaged formal and informal businesses supported in biodiversity-economy value chains against a target of 100.Evidence A · P1
  44. MWITA-FAW-2026-032World Bank reporting says PROLAC brought 33,231 hectares across Cameroon, Chad and Niger under better water and soil management—more than triple its original goal—and rehabilitated more than 2,400 hectares of polders in Chad.Evidence B · P1
  45. MWITA-RL-2026-017A study of 12,733 drone-delivered blood-product orders to 20 Rwandan health facilities found mean delivery time of 49.6 minutes, 79 minutes faster than regional blood-centre road estimates and 98 minutes faster than Google Maps estimates.Evidence A · P1
  46. MWITA-RL-2026-018The same Rwandan study estimated 7.1 fewer blood-unit expirations per month after drone delivery began, corresponding to a 67% reduction at 12 months.Evidence A · P1
  47. MWITA-RL-2026-019A 2026 staggered-rollout study of Rwandan public hospitals found lower red-blood-cell inventory and wastage after drone adoption and reductions in in-hospital mortality for postpartum hemorrhage and trauma concentrated among hospitals closer to a drone port.Evidence A · P1
  48. MWITA-CT-2026-001UN-Habitat's World Cities Report 2026 estimates that up to 3.4 billion people lack access to secure, safe and adequate housing, including more than 1.1 billion people in informal settlements and slums.Evidence A · P0
  49. MWITA-CT-2026-002UN-Habitat reports the global housing deficit increased from 251 million units in 2010 to 288 million units in 2023.Evidence A · P0
  50. MWITA-CT-2026-003The UN system's SDG 11 Global Report 2026 says four in ten urban residents still lack convenient access to public transport.Evidence A · P0
  51. MWITA-CT-2026-005India reported that by 27 January 2025 PMAY-U had sanctioned 11.864 million houses, grounded 11.250 million and completed or delivered 9.025 million.Evidence A · P0
  52. MWITA-CT-2026-006India reported 29.190774 million PMAY-G houses cumulatively completed by 9 December 2025, including 2.343066 million completed during calendar 2025 to that date.Evidence A · P0
  53. MWITA-CT-2026-007Brazil's PPA monitoring recorded 542,607 Minha Casa Minha Vida homes contracted as of 15 August 2025 against a 2025 programme indicator target of 375,000.Evidence A · P0
  54. MWITA-CT-2026-008Brazil's 2025 MCMV-FAR selection cycle provides for contracting 110,000 urban housing units, including 10,000 for specified emergency or public-works situations.Evidence A · P1
  55. MWITA-CT-2026-009Brazil's government reported the simultaneous handover of 1,876 Minha Casa Minha Vida units across five states on 1 August 2025.Evidence A · P1
  56. MWITA-CT-2026-010Kenya's Government Delivery Unit reported 130,988 affordable housing units under construction in March 2025, up from 8,872 units in 2022.Evidence A · P0
  57. MWITA-CT-2026-011South Africa's Department of Human Settlements reported 17,859 title deeds registered in 2024/25 against an annual target of 16,000.Evidence A · P1
  58. MWITA-CT-2026-012South Africa identified 100 blocked housing projects in its 2024/25 business plan and reported 24 had been unblocked by year end.Evidence A · P1
  59. MWITA-CT-2026-013Western Cape's 2025 economic review recorded registered housing demand of 643,377 units, 14.6% higher than previously reported, despite 132,705 housing opportunities delivered over the preceding decade.Evidence A · P0
  60. MWITA-CT-2026-014World Bank project monitoring reported more than 150,000 Sindh flood-reconstruction houses completed with cash-grant support by June 2025.Evidence B · P0
  61. MWITA-CT-2026-015The Sindh housing reconstruction project anticipated 410,000 multi-hazard-resistant houses by 2027; this is a future target distinct from the 150,000-plus completions reported in 2025.Evidence B · P1
  62. MWITA-CT-2026-016Morocco's High Atlas Development Agency reported that 46,650 families had completed construction or rehabilitation of earthquake-affected homes by 10 July 2025.Evidence A · P0
  63. MWITA-CT-2026-017China's Ministry of Transport reported 341 urban rail lines operating over 11,651 km at end-2025, 728 km more than a year earlier.Evidence A · P0
  64. MWITA-CT-2026-018China's 2025 urban rail passenger volume rose 3.2% to 33.224 billion trips while public bus and trolleybus trips fell 5.5% to 36.566 billion.Evidence A · P0
  65. MWITA-CT-2026-019Jakarta's statistics office recorded 4,057,868 MRT trips, 119,315 LRT trips and 37,463,134 TransJakarta trips in December 2025.Evidence A · P1
  66. MWITA-CT-2026-020Saudi Arabia's transport authority reported 32.1 million Riyadh Metro passenger trips in the fourth quarter of 2025.Evidence A · P0
  67. MWITA-CT-2026-021World Bank project monitoring reported 39 km of roads and 45 km of pedestrian walkways completed across seven Somali cities by 2025, with another 51 km still under construction.Evidence B · P0
  68. MWITA-CT-2026-022The Somalia urban resilience project reported nearly 700,000 people benefiting from improved access to climate-resilient urban infrastructure between 2020 and 2025.Evidence B · P0
  69. MWITA-CT-2026-023World Bank reporting says a Yemen connectivity project rehabilitated more than 150 km of roads and provided 1.2 million people with all-weather road access.Evidence B · P1
  70. MWITA-CT-2026-024World Bank reporting says Tunisia's Road Transport Corridors Project built more than 137 km of roads and reported more than 373,000 beneficiaries.Evidence B · P1
  71. MWITA-CT-2026-028The World Bank reported that more than 30 active projects in Latin America and the Caribbean increased resilience for over 24 million people through several different modalities.Evidence B · P1
  72. MWITA-CT-2026-029World Bank reporting says Colombia incorporated risk management into the construction, renovation or upgrading of nearly 2,000 km of public roads under a disaster-risk policy operation.Evidence B · P0
  73. MWITA-CT-2026-032Singapore reported Design for Manufacturing and Assembly adoption in new development gross floor area rose from about 61% in 2023 to 68% in 2024.Evidence A · P1
  74. MWITA-CT-2026-033CETUD and the World Bank had established a multidimensional impact-evaluation programme for Dakar's BRT and TER by August 2025, but the country brief reports the evaluation design and data systems rather than completed impact estimates.Evidence A · P1
  75. MWITA-CT-2026-034ADB's Urban Financing Partnership Facility supported approval of 13 new technical-assistance projects totaling US$19.52 million in 2025.Evidence A · P1
  76. MWITA-BL-2026-001China's NMPA conditionally approved amimestrocel injection through priority review for steroid-refractory acute graft-versus-host disease with predominant gastrointestinal involvement in patients aged 14 years and older.Evidence A · P1
  77. MWITA-BL-2026-002China's NMPA conditionally approved ciltacabtagene autoleucel for adults with relapsed or refractory multiple myeloma after at least three prior lines of therapy meeting the stated regimen conditions.Evidence A · P1
  78. MWITA-BL-2026-003In an open-label Indian phase 1/2 study of talicabtagene autoleucel, 37 of 51 efficacy-evaluable patients with relapsed or refractory B-cell malignancies responded, an overall response rate of 73% (95% CI 59%-83%).Evidence A · P1
  79. MWITA-BL-2026-004The same Indian talicabtagene autoleucel study reported grade 3-or-worse neutropenia in 55 of 57 treated patients and two treatment-related deaths.Evidence A · P1
  80. MWITA-BL-2026-005Anvisa authorized a phase 1/2 Brazilian clinical study of an investigational gene therapy for children with spinal muscular atrophy type 1; potential production in Brazil is contingent on later registration and successful technology transfer.Evidence A · P1
  81. MWITA-BL-2026-006Anvisa kept Elevidys commercialization, distribution, manufacturing, import, promotion and use temporarily suspended in September 2025 while investigating fatal acute liver failure reported with the AAVrh74 platform; about ten Brazilian patients had received Elevidys without similar reported cases at that time.Evidence A · P1
  82. MWITA-BL-2026-017As of 1 May 2025, WHO's mRNA technology-transfer programme comprised a South African hub and 14 manufacturing partners; the first transfer to South Africa's Biovac was completed in September 2024.Evidence A · P1
  83. MWITA-BL-2026-018WHO's 2025 African Region report states that COVID-19 sequencing output increased from fewer than 5,500 sequences in 2020 to more than 183,500 in 2025, while mpox sequencing rose from fewer than 500 in July 2024 to more than 2,700 in November 2025.Evidence A · P1
  84. MWITA-BL-2026-019FDA granted accelerated approval to Kresladi in March 2026 for severe leukocyte adhesion deficiency type I based on increased neutrophil CD18 and CD11a expression as a surrogate reasonably likely to predict clinical benefit.Evidence A · P1
  85. MWITA-BL-2026-020In November 2025 FDA added a Boxed Warning for serious liver injury and acute liver failure to Elevidys and restricted the indication to ambulatory patients aged four years and older after fatal acute liver-failure reports in non-ambulatory patients.Evidence A · P1
  86. MWITA-BL-2026-021FDA approved Waskyra in December 2025 for eligible patients with Wiskott-Aldrich syndrome and no suitable matched related stem-cell donor, using regulatory flexibility and post-market commitments; the applicant was a nonprofit.Evidence A · P1
  87. MWITA-DS-2026-002China reported 7.92 million births and 11.31 million deaths in 2025, corresponding to natural population growth of -2.41 per thousand.Evidence A · P1
  88. MWITA-DS-2026-006Japan's Statistical Handbook reports that people aged 65 and over were 29.3% of the population in 2024, while 38.7% for 2070 is a projection rather than an observed outcome.Evidence A · P1
  89. MWITA-DS-2026-007South Korea registered 20,035 births and 30,283 deaths in February 2025, leaving natural change at -10,248 even though births were 3.2% higher than a year earlier.Evidence A · P1
  90. MWITA-DS-2026-013Eurostat reported 158,400 minor first-time asylum applicants in the EU in 2025, 23.7% of all first-time applicants; 13.3% of those minors were unaccompanied.Evidence A · P1
  91. MWITA-DS-2026-016Statistics South Africa's General Household Survey 2025 found that 22.0% of households considered their food access inadequate or severely inadequate, 4.2 percentage points above 2019.Evidence A · P1
  92. MWITA-MFG-2026-001UNIDO estimated global manufacturing production increased 0.50% quarter on quarter in Q4 2025.Evidence A · P0
  93. MWITA-MFG-2026-002UNIDO reported China led regional manufacturing growth in Q4 2025, followed by the rest of Asia-Pacific, while output elsewhere stagnated or declined and Africa recorded moderate growth.Evidence A · P0
  94. MWITA-MFG-2026-003UNIDO reported Q4 2025 output in lower-technology manufacturing rose only 0.2%, while medium-high and high-technology industries sustained quarterly growth above 1%. Evidence A · P1
  95. MWITA-MFG-2026-004The 2025 GVC Development Report put global-value-chain trade at 46.3% of world trade in 2024, down only modestly from a 48% peak in 2022.Evidence A · P0
  96. MWITA-MFG-2026-005The GVC Development Report 2025 concluded recent rewiring mostly benefited economies already established as suppliers rather than automatically deconcentrating production.Evidence A · P0
  97. MWITA-MFG-2026-007IEA estimated full implementation of 2025 rare-earth export controls could put US$6.5 trillion per year of downstream production outside China at risk.Evidence A · P0
  98. MWITA-MFG-2026-008IEA estimated critical-mineral mining investment fell 9% in 2025, with battery-metals spending down more than 20% and lithium-company investment down about 40%.Evidence A · P0
  99. MWITA-MFG-2026-009IEA estimated advanced-economy public-finance commitments for critical minerals reached about US$65 billion in 2025, more than four times 2023, while warning commitments and disbursements differ.Evidence A · P1
  100. MWITA-MFG-2026-010IEA estimated Latin America and the Caribbean produces around one-quarter of global lithium but refines only about one-fifth of its mined output of key energy minerals other than lithium.Evidence A · P0
  101. MWITA-MFG-2026-011IFR counted 542,000 industrial robots installed worldwide in 2024, the fourth consecutive year above 500,000.Evidence A · P0
  102. MWITA-MFG-2026-012IFR counted 295,000 industrial robots installed in China in 2024, 54% of global deployments, with operational stock above two million.Evidence A · P0
  103. MWITA-MFG-2026-013IFR counted a record 9,100 industrial robot installations in India in 2024, 7% more than in 2023.Evidence A · P1
  104. MWITA-MFG-2026-014IFR counted 30,600 industrial robot installations in Korea in 2024, down 3%, and described annual installations as roughly flat near 31,000 since 2019.Evidence A · P1
  105. MWITA-MFG-2026-015China's statistics office reported production of 773,074 industrial robots in 2025, up 28.0% year on year.Evidence A · P0
  106. MWITA-MFG-2026-016China's statistics office reported 484.3 billion integrated circuits produced in 2025, up 10.9% year on year.Evidence A · P0
  107. MWITA-MFG-2026-017China's official communiqué reported manufacturing value added grew 6.4% in 2025.Evidence A · P1
  108. MWITA-MFG-2026-018India reported in April 2026 that commercial production had commenced at two of ten approved semiconductor projects, with two more expected to start during 2026.Evidence A · P0
  109. MWITA-MFG-2026-019India reported electronics-goods production of about ₹12 trillion in 2024/25, roughly six times the nominal value in 2014/15.Evidence A · P0
  110. MWITA-MFG-2026-020India reported 38 Electronics Components Manufacturing Scheme plants operational and 16 in advanced construction by 17 August 2026.Evidence A · P0
  111. MWITA-MFG-2026-021India's 106 approved ECMS projects carried projected investment of ₹695.48 billion, projected production of ₹5.341 trillion and expected direct employment of 74,628.Evidence A · P1
  112. MWITA-MFG-2026-022India approved the National Critical Mineral Mission with ₹163 billion government expenditure and ₹180 billion expected PSU investment over seven years.Evidence A · P1
  113. MWITA-MFG-2026-023India reported 58 entities pledging 850,000 tonnes per year of critical-mineral recycling capacity under its incentive scheme, versus a 270,000-tonne target.Evidence A · P0
  114. MWITA-MFG-2026-024Indonesia broke ground in June 2025 on an integrated battery project designed for 6.9 GWh of cell capacity with a stated later expansion to 15 GWh.Evidence A · P0
  115. MWITA-MFG-2026-025Indonesia's government described HLI Green Power's Karawang facility as operating with 10 GWh annual nameplate capacity, equivalent by design to batteries for about 150,000 EVs.Evidence A · P0
  116. MWITA-MFG-2026-026Malaysia's statistics office reported manufacturing sales of RM1.97 trillion in 2025, up 4.2% in nominal value from 2024.Evidence A · P1
  117. MWITA-MFG-2026-027INEGI recorded 3,953,494 light vehicles produced in Mexico in 2025, 0.9% fewer than in 2024.Evidence A · P0
  118. MWITA-MFG-2026-028Statistics South Africa reported total manufacturing production fell 1.3% in 2025 from 2024.Evidence A · P0
  119. MWITA-MFG-2026-029Morocco's 2025 industry survey reported 2024 industrial production value of MAD842 billion, up 12%, and industrial employment of 1,038,133, a net increase of 42,714 jobs.Evidence A · P1
  120. MWITA-MFG-2026-030Saudi Arabia's preliminary industrial index showed manufacturing output 6.3% higher year on year in September 2025.Evidence A · P1
  121. MWITA-MFG-2026-031Brazil's November 2025 tax-advantaged debenture policy estimated potential annual investment of R$5.2 billion in strategic-mineral projects, including R$3.7 billion for transformation and R$1.5 billion for mining and beneficiation.Evidence A · P1
  122. MWITA-MFG-2026-032Brazil's 2026 official investor guide says domestic production of high-purity inputs for energy-transition value chains remains incipient despite substantial critical-mineral potential.Evidence A · P0
  123. MWITA-SG-2026-009Brazil's Ministry of Finance reported 79 authorized fixed-odds betting companies and 25.2 million Brazilian participants during 2025.Evidence A · P1
  124. MWITA-SG-2026-010Brazil's betting regulator reported 25,245,319 unique bettor CPFs but 87,671,439 active operator accounts and 100,775,427 active brand accounts in its cumulative reporting, demonstrating that account totals and people totals are different denominators.Evidence A · P1
  125. MWITA-SG-2026-011Brazil's federal centralized betting self-exclusion platform has been in force since December 2025 and can block a person from all federally authorized betting houses.Evidence A · P1
  126. MWITA-SG-2026-012Participation in India's Khelo India Para Games increased from 1,068 athletes in the 2023 edition to 1,233 in the March 2025 edition.Evidence A · P1
  127. MWITA-SG-2026-014In a Chinese randomized trial of adolescents with excess body weight, an eight-week supervised adaptive-VR sports program reduced fat mass by 4.28 kg versus control (95% CI 2.22 to 6.35 kg reduction), while supervised physical sports reduced it by 5.06 kg versus control (95% CI 2.98 to 7.13 kg reduction); the two active interventions did not differ significantly.Evidence A · P1
  128. MWITA-SG-2026-015The same trial reported minimal injuries in 7 REVERIE participants (7.69%) and 12 physical-sports participants (13.48%), with no serious adverse events.Evidence A · P1
  129. MWITA-SG-2026-017In a 2025 Chinese randomized trial of 160 university students, eight weeks of team competition, points, leaderboards, feedback and rewards on top of the same watch-app platform and activity goals produced 2,114 more daily steps and 28 more daily minutes of moderate-to-vigorous activity than monitoring alone.Evidence A · P1
  130. MWITA-SG-2026-018The gamified mHealth arm also showed eight-week between-group improvements of 0.54 kg in skeletal muscle, 0.46 percentage points in body-fat reduction, 6.5 seconds in run time and 2 points in depressive-symptom reduction, while body weight and BMI differences were not significant.Evidence B · P1
  131. MWITA-SG-2026-019A 2025 meta-analysis of 22 randomized trials with 1,312 older adults found that exergame muscle-strength estimates varied by comparator and were too heterogeneous for a general efficacy conclusion: I-squared was 95%-98%, chair-stand performance was not significantly different from nonexercise controls, and handgrip results against nonexercise controls were nonrobust.Evidence A · P1
  132. MWITA-SG-2026-020WHO reported that 31% of adults worldwide, about 1.8 billion people, did not meet recommended physical-activity levels in 2022, about five percentage points more than in 2010.Evidence A · P1
  133. MWITA-FB-2026-002Chinese enterprises above the designated size recorded CNY 465.3 billion in cosmetics retail sales in 2025, 5.1% above 2024 in nominal terms.Evidence A · P1
  134. MWITA-FB-2026-004Korea's MFDS reported 2025 cosmetics exports of USD 11.4 billion, 11.8% above 2024, and a cosmetics trade surplus of USD 10.1 billion.Evidence A · P1
  135. MWITA-FB-2026-013Brazil's Anvisa received 1,910 cosmetic adverse-event notifications in January-June 2025, of which 1,798 (94.1%) concerned toothpaste.Evidence A · P1
  136. MWITA-FB-2026-014From 28 August 2025, Brazilian cosmetics companies became required to notify serious adverse events through Notivisa under Anvisa's cosmetovigilance framework.Evidence A · P1
  137. MWITA-FB-2026-017Amorepacific Group reported 2025 revenue of KRW 4.6232 trillion, up 8.5%, and operating profit of KRW 368 billion, up 47.6%.Evidence B · P1
  138. MWITA-FB-2026-018Kao reported that its expanded Kirei Skin AI used 25 models to estimate 77 skin attributes from facial images, processed each suitable image in under ten minutes, and was analyzing about 730 images per month in its research operations in 2025.Evidence B · P1
  139. MWITA-FB-2026-019Shiseido's 2025 ULTIMUNE launch cites an eight-week clinical test in 34 women reporting improvements of 51% in radiance, 38% in firmness and 63% in smoothness.Evidence C · P1
  140. MWITA-FB-2026-020The same launch reports consumer sensory-test responses from 107 women, including 98% saying after four weeks that the serum reduced visible aging signs.Evidence C · P1
  141. MWITA-MBLO-2026-001Around 80% of international merchandise trade by volume is carried by sea.Evidence A · P0
  142. MWITA-MBLO-2026-002UNCTAD forecast seaborne trade volume growth of only 0.5% in 2025.Evidence A · P0
  143. MWITA-MBLO-2026-003UNCTAD reported long-distance rerouting drove nearly 6% growth in maritime ton-miles in 2024.Evidence A · P0
  144. MWITA-MBLO-2026-004Asia's share of global container-ship port calls rose from 59% in H1 2018 to 63% in H2 2024, while Europe's fell from 21% to 17%.Evidence A · P1
  145. MWITA-MBLO-2026-005UNCTAD reported LNG bunkering availability at around 200 ports in 2024.Evidence A · P1
  146. MWITA-MBLO-2026-006The IMO Net-Zero Framework was approved in April 2025, but the October 2025 adoption meeting was adjourned for one year; it was not yet legally adopted on the cited status page.Evidence A · P0
  147. MWITA-MBLO-2026-007The approved draft framework applies to oceangoing ships over 5,000 gross tonnage, which IMO says account for over 85% of global shipping emissions.Evidence A · P0
  148. MWITA-MBLO-2026-008Singapore handled a record 44.66 million TEU in 2025, 8.6% more than 2024.Evidence A · P0
  149. MWITA-MBLO-2026-009Singapore recorded 3.22 billion gross tonnage of vessel arrivals in 2025, up 3.5%.Evidence A · P1
  150. MWITA-MBLO-2026-010Singapore sold 56.77 million tonnes of marine fuel in 2025, including 1.95 million tonnes of alternative marine fuels versus 1.35 million in 2024.Evidence A · P0
  151. MWITA-MBLO-2026-011Chinese ports handled 18.338 billion tonnes of cargo in 2025, up 4.2%.Evidence A · P0
  152. MWITA-MBLO-2026-012Chinese ports handled 354 million TEU in 2025, up 6.8%; foreign-trade container throughput rose 9.8%.Evidence A · P0
  153. MWITA-MBLO-2026-013China's port passenger throughput was 79.49 million in 2025, up 0.7%, with coastal volume down 0.7% and inland volume up 30.2%.Evidence A · P1
  154. MWITA-MBLO-2026-014China had 439 coastal interprovincial container ships of at least 700 TEU at end-2025 with 1.026 million TEU capacity, 3.0% higher than end-2024.Evidence A · P1
  155. MWITA-MBLO-2026-015The average age of China's coastal interprovincial container fleet reached 8.8 years at end-2025, and 12.1% of vessels were at least 20 years old.Evidence A · P1
  156. MWITA-MBLO-2026-016India's major ports handled 915.17 million tonnes in FY2025-26, 7.06% more year on year and above the 904 million-tonne target.Evidence A · P0
  157. MWITA-MBLO-2026-017India reported ₹14,953 crore of major-port-related capex including internal resources and PPP in FY2025-26, versus ₹9,708 crore a year earlier.Evidence A · P1
  158. MWITA-MBLO-2026-018India added 94 ships and 2.567 million DWT to the Indian flag in FY2025-26, versus 45 ships and 0.772 million DWT the prior year.Evidence A · P1
  159. MWITA-MBLO-2026-019India's ministry reported the first indigenous hydrogen fuel-cell vessel was flagged off on 11 December 2025 for commercial tourist operations on National Waterway 1.Evidence A · P1
  160. MWITA-MBLO-2026-020Suez Canal transits fell 3.4% from 13,213 vessels in 2024 to 12,758 in 2025.Evidence A · P0
  161. MWITA-MBLO-2026-021Suez Canal cargo traffic increased 1.4% in 2025 even as net tonnage fell 0.5%; northbound cargo rose 20.4% while southbound cargo fell 5.4%.Evidence A · P0
  162. MWITA-MBLO-2026-022Suez Canal traffic dropped from 26,434 vessels in 2023 to 13,213 in 2024 and dollar revenue fell 61% to $3.991 billion amid the Red Sea crisis.Evidence A · P0
  163. MWITA-MBLO-2026-023The Panama Canal recorded 13,404 transits in FY2025, up 19.3% from 11,240 in FY2024.Evidence A · P0
  164. MWITA-MBLO-2026-024Panama Canal traffic reached 489.2 million PC/UMS tonnes in FY2025, up about 15.6% from FY2024.Evidence A · P0
  165. MWITA-MBLO-2026-025The Panama Canal reported B/.5.705 billion revenue and B/.4.134 billion net profit in FY2025.Evidence A · P1
  166. MWITA-MBLO-2026-026In June 2026 the Panama Canal reported maintaining 38 daily transits and forecast no transit restrictions through 31 December 2026 while using preventive water-saving measures.Evidence A · P1
  167. MWITA-MBLO-2026-027The Port of Mombasa handled a record 45.45 million tonnes in 2025, 10.0% more than 2024.Evidence A · P0
  168. MWITA-MBLO-2026-028Mombasa handled 2.11 million TEU in 2025, 5.5% more than 2024.Evidence A · P0
  169. MWITA-MBLO-2026-029Mombasa transit cargo rose 19.5% to 15.88 million tonnes in 2025.Evidence A · P0
  170. MWITA-MBLO-2026-030KPA states Mombasa's two container terminals currently provide 2.3 million TEU annual capacity, while planned berths 23 and 19B would raise it to 3.1 million TEU.Evidence A · P1
  171. MWITA-MBLO-2026-031Brazilian ports moved 1.28 billion tonnes in January–November 2025, 4.97% more than the same period of 2024.Evidence A · P0
  172. MWITA-MBLO-2026-032Southeast Brazil's cabotage volume reached 137.4 million tonnes in 2025, up 5.91%.Evidence A · P1
  173. MWITA-MBLO-2026-033FAO forecast global fisheries and aquaculture production at 197 million tonnes in 2025, with aquaculture at 104.2 million tonnes and capture fisheries at 92.9 million tonnes.Evidence A · P1
  174. MWITA-MBLO-2026-034South Africa's amended 2025/26 performance plan targeted 70% completion status across 18 Operation Phakisa marine transport and manufacturing initiatives.Evidence A · P1
  175. MWITA-MBLO-2026-035Ghana Ports and Harbours Authority commissioned 15 new trucks into service at Tema Port in May 2025.Evidence A · P2
  176. MWITA-PW-2026-021A 2025 randomized trial of 271 inactive desk workers with elevated blood pressure found a three-month sedentary-behavior intervention did not significantly change workplace satisfaction, productivity or health-related quality of life; only vigor improved among mood measures.Evidence A · P1
  177. MWITA-IFD-2026-018The Global Fund Results Report 2025 reports 25.6 million people on antiretroviral therapy in 2024 in countries and regions where it invests.Evidence B · P1
  178. MWITA-IFD-2026-019The Global Fund reports 70 million lives saved since 2002 across countries where it invests, using disease-burden and impact estimates from WHO, UNAIDS and modeling partners.Evidence B · P1
  179. MWITA-IFD-2026-020Gavi reports that zero-dose children in 57 supported lower-income countries declined to 10.2 million in 2024, 5% below 2023.Evidence B · P1
  180. MWITA-IFD-2026-021Gavi reports DTP3 immunization coverage of 82% in supported countries in 2024, up from 78% in 2021 and near the 83% pre-pandemic level in 2019.Evidence B · P1
  181. MWITA-CSE-2026-001India's HCES estimated 2023-24 average monthly per-capita consumption expenditure excluding imputed free welfare items at ₹4,122 in rural areas and ₹6,996 in urban areas.Evidence A · P1
  182. MWITA-CSE-2026-002Food represented 47.04% of rural MPCE in India's 2023-24 HCES.Evidence A · P1
  183. MWITA-CSE-2026-003Food represented 39.68% of urban MPCE in India's 2023-24 HCES.Evidence A · P1
  184. MWITA-CSE-2026-004Cereals accounted for 4.99% of rural MPCE and 3.76% of urban MPCE in India's 2023-24 HCES.Evidence A · P1
  185. MWITA-CSE-2026-005Non-food expenditure represented approximately 53% of rural and 60% of urban MPCE in India's 2023-24 HCES.Evidence A · P1
  186. MWITA-CSE-2026-006India's official HCES summary reported rural consumption Gini falling from 0.266 to 0.237 and urban Gini from 0.314 to 0.284 between 2022-23 and 2023-24.Evidence A · P1
  187. MWITA-CSE-2026-007The official HCES release reported nominal MPCE growth for the bottom 5% of about 22% in rural India and 19% in urban India between 2022-23 and 2023-24.Evidence A · P1
  188. MWITA-CSE-2026-008India's HCES measures consumption through the value of goods and services acquired for consumption, whether or not payment occurred in the same reference period.Evidence A · P1
  189. MWITA-CSE-2026-009China's 2025 nationwide per-capita disposable income was ¥43,377, up 5.0% nominally and 5.0% in real terms from 2024.Evidence A · P1
  190. MWITA-CSE-2026-010China's 2025 median per-capita disposable income was ¥36,231, 83.5% of the average, and grew 4.4% nominally.Evidence A · P1
  191. MWITA-CSE-2026-011China's 2025 per-capita consumption expenditure was ¥29,476, up 4.4% nominally and 4.4% in real terms.Evidence A · P1
  192. MWITA-CSE-2026-012In 2025 China's per-capita consumption expenditure was ¥35,869 in urban areas and ¥20,259 in rural areas; nominal growth was 3.8% and 5.1%, respectively.Evidence A · P1
  193. MWITA-CSE-2026-013Food, tobacco and alcohol represented 29.3% of China's per-capita consumption expenditure in 2025, down 0.5 percentage point; the shares were 28.3% urban and 31.8% rural.Evidence A · P1
  194. MWITA-CSE-2026-014China's 2025 per-capita service consumption expenditure was ¥13,602, up 4.5%, and accounted for 46.1% of total expenditure, unchanged from 2024.Evidence A · P1
  195. MWITA-CSE-2026-015China's per-capita expenditure on household facilities, articles and services rose 7.7% nominally in 2025.Evidence A · P1
  196. MWITA-CSE-2026-016China's per-capita transport and communications expenditure rose 8.3% nominally in 2025.Evidence A · P1
  197. MWITA-CSE-2026-017China's per-capita education, culture and recreation expenditure rose 9.4% nominally in 2025.Evidence A · P1
  198. MWITA-CSE-2026-018China's per-capita healthcare expenditure rose 1.0% nominally in 2025.Evidence A · P1
  199. MWITA-CSE-2026-019China's 2025 per-capita disposable income ranged from ¥10,150 in the low-income group to ¥103,778 in the high-income group in NBS's five-group distribution.Evidence A · P1
  200. MWITA-CSE-2026-020Mexico's ENIGH 2024 reported average monthly current household income of MXN25,955, 10.6% above 2022.Evidence A · P1
  201. MWITA-CSE-2026-021Mexico's ENIGH 2024 reported average monthly current monetary household spending of MXN15,891.Evidence A · P1
  202. MWITA-CSE-2026-022In Mexico's ENIGH 2024, food, beverages and tobacco represented 37.7% of current monetary household spending and transport and communications 19.5%.Evidence A · P1
  203. MWITA-CSE-2026-023Mexico's ENIGH 2024 reported average quarterly household health spending of MXN2,424, equal to 3.7% of current monetary spending.Evidence A · P1
  204. MWITA-CSE-2026-024ENIGH 2024 reported men's average monthly monetary income was MXN4,111 higher than women's in Mexico.Evidence A · P1
  205. MWITA-CSE-2026-025ENIGH 2024 reported average income among people self-identifying as Indigenous or speaking an Indigenous language was 26.0% below Mexico's national average.Evidence A · P1
  206. MWITA-CSE-2026-027Brazil's 2025 national accounts recorded household consumption expenditure of R$8.1 trillion.Evidence A · P1
  207. MWITA-CSE-2026-028Brazil's household consumption expenditure was flat quarter-on-quarter in Q4 2025 after seasonal adjustment and 1.0% above Q4 2024.Evidence A · P1
  208. MWITA-CSE-2026-029Brazil's nominal monthly per-capita household income was R$2,316 in 2025.Evidence A · P1
  209. MWITA-CSE-2026-030Brazil's 2025 nominal monthly per-capita household income ranged from R$1,219 in Maranhão to R$4,538 in the Federal District.Evidence A · P1
  210. MWITA-CSE-2026-031Brazil's official IPCA consumer-price index rose 4.26% over 2025.Evidence A · P1
  211. MWITA-CSE-2026-032Japan's two-or-more-person households spent an average ¥314,001 per month in 2025, up 4.6% nominally and 0.9% in real terms.Evidence A · P1
  212. MWITA-CSE-2026-033Japan's worker households with two or more persons had average monthly income of ¥653,901 in 2025, up 2.8% nominally but down 0.9% in real terms.Evidence A · P1
  213. MWITA-CSE-2026-034Japan's worker households with two or more persons averaged ¥346,297 monthly consumption expenditure in 2025, up 6.5% nominally and 2.7% in real terms.Evidence A · P1
  214. MWITA-CSE-2026-036South Korean households averaged KRW2.950 million monthly consumption expenditure in Q1 2025, up 1.4% nominally but down 0.7% at 2020 prices year-on-year.Evidence A · P1
  215. MWITA-CSE-2026-037South Korean average monthly household income was KRW5.351 million in Q1 2025, up 4.5% nominally and 2.3% at 2020 prices year-on-year.Evidence A · P1
  216. MWITA-CSE-2026-038South Korean household expenditure on housing, water, electricity and fuels rose 5.8% nominally and 3.8% in real terms year-on-year in Q1 2025.Evidence A · P1
  217. MWITA-CSE-2026-039In South Korea Q1 2025 household transportation spending fell 3.7% nominally and 5.8% in real terms, while clothing and footwear fell 4.7% nominally and 6.4% in real terms year-on-year.Evidence A · P1
  218. MWITA-CSE-2026-040South Korea's average propensity to consume was 69.8% in Q1 2025, 2.1 percentage points below Q1 2024.Evidence A · P1
  219. MWITA-CSE-2026-041In South Korea Q1 2025 the lowest income quintile's average propensity to consume was 147.6%, versus 56.7% for the highest quintile.Evidence A · P1
  220. MWITA-CSE-2026-042Indonesia's economy grew 5.11% in 2025, with GDP per capita at current prices of IDR83.7 million.Evidence A · P1
  221. MWITA-HR-2026-001IFR counted about 20.1 million consumer service robots sold in 2024, 11% more than in 2023.Evidence B · P1
  222. MWITA-HR-2026-002Robots for domestic tasks represented 97% of IFR-counted consumer service-robot sales in 2024.Evidence B · P1
  223. MWITA-HR-2026-004IFR counted almost 200,000 professional service robots sold in 2024, up 9%.Evidence B · P1
  224. MWITA-HR-2026-005IFR reported the robot-as-a-service fleet grew 31% in 2024.Evidence B · P1
  225. MWITA-HR-2026-006China published GB/T 46505.1-2025 for intelligent household-appliance application scenarios, effective 1 May 2026.Evidence A · P1
  226. MWITA-HR-2026-007GB/T 46505.1-2025 defines standalone, linked and system modes for smart-appliance scenarios.Evidence A · P1
  227. MWITA-HR-2026-008The Chinese standard covers interaction, intelligent control, environmental and health management, load/resource management, maintenance and scenario customization.Evidence A · P1
  228. MWITA-HR-2026-009GB/T 46505.1-2025 defines five smart-scenario levels from L1 to L5.Evidence A · P1
  229. MWITA-HR-2026-014China's 2026 AI-plus-consumption guideline promotes robots for elderly care, companionship and daily assistance.Evidence A · P1
  230. MWITA-HR-2026-015The guideline encourages rental, sharing and trial use of AI products and permits local subsidy policies for next-generation smart terminals.Evidence A · P1
  231. MWITA-HR-2026-016Samsung reported more than 410 million SmartThings users globally as of July 2025 and more than 23 million in South Korea.Evidence B · P1
  232. MWITA-HR-2026-017Samsung reported 33 million home appliances connected to SmartThings by November 2025, about 30% more than at the year's start.Evidence B · P1
  233. MWITA-HR-2026-018Samsung stated SmartThings integrated more than 4,500 models from over 380 partners in 2025.Evidence B · P1
  234. MWITA-HR-2026-019In Samsung's 1,880-person 2024 online survey, 'help/assist', cleaning, cooking, automatic and easy were frequent open-text expectations for household AI.Evidence B · P1
  235. MWITA-HR-2026-020Voice/tell/talk was the most frequent AI-interaction theme in Samsung's survey, with 203 mentions.Evidence B · P1
  236. MWITA-HR-2026-021Samsung reported 'minimizing resource usage' was selected by 49% of South Korean, 59% of UK and 67% of US respondents as a relevant AI-driven home experience.Evidence B · P1
  237. MWITA-HR-2026-022Samsung announced a Family Care function that alerts relatives when expected movement or activity is not detected.Evidence B · P1
  238. MWITA-HR-2026-023Samsung announced that compatible robot vacuums could be used to look for signs of an emergency within Family Care.Evidence B · P1
  239. MWITA-HR-2026-025Matter 1.5 added camera support including live audio/video, two-way communication and local or remote access.Evidence A · P1
  240. MWITA-HR-2026-027Matter 1.5 added a unified closure model and enhanced energy-management capabilities.Evidence A · P1
  241. MWITA-HR-2026-030Honda began corporate sales of the UNI-ONE hands-free personal mobility device in Japan on 24 September 2025.Evidence B · P1
  242. MWITA-HR-2026-033Honda listed monthly UNI-ONE corporate contract fees of ¥80,000–¥120,000 depending on volume and term, plus a ¥55,000 daily short-term rental.Evidence B · P1
  243. MWITA-HR-2026-034Google launched Gemini for Home in October 2025 to replace Google Assistant on compatible smart speakers and displays.Evidence B · P1
  244. MWITA-HR-2026-035Google announced Gemini features for cameras, doorbells and the Home app, including natural-language home-event understanding.Evidence B · P1
  245. MWITA-HR-2026-036Google stated advanced Gemini Live and AI-powered notification capabilities would require Google Home Premium.Evidence B · P1
  246. MWITA-HR-2026-037Amazon announced Alexa+ at US$19.99 per month and included it for Prime members.Evidence B · P1
  247. MWITA-HR-2026-038Amazon announced Alexa+ would begin rolling out in waves to US households, initially prioritizing selected Echo Show devices.Evidence B · P1
  248. MWITA-HR-2026-039Amazon announced Alexa+ could create complex smart-home routines from voice requests.Evidence B · P1
  249. MWITA-FF-2026-001Singapore's food regulator reported pre-market approvals since 2020 spanning cultivated products from Eat Just and Vow, the precision-fermented Solein ingredient and 16 insect species.Evidence A · P1
  250. MWITA-FF-2026-002Singapore subjects novel foods to pre-market safety assessment before approval.Evidence A · P1
  251. MWITA-FF-2026-003Singapore reported completed collaborative research on new-approach toxicology methods for assessing novel alternative proteins.Evidence A · P1
  252. MWITA-FF-2026-004Singapore's March 2026 register lists approved foods made through multiple technology routes, including cultivated biomass and ingredients produced by precision fermentation.Evidence A · P1
  253. MWITA-FF-2026-005Singapore's authorization register identifies the producing organism and product form for precision-fermentation ingredients, making approvals narrower than a platform-wide licence.Evidence A · P1
  254. MWITA-FF-2026-006Australia and New Zealand gazetted permission for cell-cultured quail as food on 18 June 2025.Evidence A · P1
  255. MWITA-FF-2026-007FSANZ assessed the cultured-quail cell line as genetically stable and concluded that toxicological, nutritional, allergenic and manageable microbiological issues did not preclude the proposed use.Evidence A · P1
  256. MWITA-FF-2026-009The UK FSA launched a two-year regulatory sandbox for animal cell-cultivated products in March 2025.Evidence A · P1
  257. MWITA-FF-2026-010The UK sandbox is designed to gather production and safety evidence so regulators can assess future applications more efficiently.Evidence A · P1
  258. MWITA-FF-2026-011UK guidance issued in December 2025 classifies animal-cell-cultivated foods as products of animal origin for hygiene-law purposes.Evidence A · P1
  259. MWITA-FF-2026-012The first UK sandbox guidance addresses allergenicity assessment and nutritional-quality evidence for cell-cultivated products.Evidence A · P1
  260. MWITA-FF-2026-013UK regulators scheduled further cell-cultivated-product guidance during 2026.Evidence A · P1
  261. MWITA-FF-2026-014The UK's Genetic Technology (Precision Breeding) Regulations 2025 came into force on 13 November 2025.Evidence A · P1
  262. MWITA-FF-2026-015A UK precision-bred food applicant must first obtain Defra status and a marketing notice before applying to FSA for food or feed marketing authorization.Evidence A · P1
  263. MWITA-FF-2026-016China's NHC and MIIT jointly solicited food-biomanufacturing application directions and cases in August 2025.Evidence A · P1
  264. MWITA-FF-2026-017The Chinese call explicitly covers synthetic biology, fermentation engineering and enzyme engineering across food ingredients, additives, food-contact products and processing.Evidence A · P1
  265. MWITA-FF-2026-018Shanghai's 2026–2030 food-technology plan targets an industrial output value above RMB 150 billion by 2030.Evidence A · P1
  266. MWITA-FF-2026-019Shanghai targets 8–10 leading niche food-tech firms and one or two synthetic-biology food-company listings by 2030.Evidence A · P1
  267. MWITA-FF-2026-020Beijing Pinggu's 2025–2027 action plan positions alternative proteins as an integrated technology-to-application industrial ecosystem.Evidence A · P1
  268. MWITA-FF-2026-021FAO's 2025 precision-fermentation report maps production stages, potential food-safety hazards, preventive controls and regulatory approaches across jurisdictions.Evidence A · P1
  269. MWITA-FF-2026-022FAO frames the precision-fermentation publication as a reference for national food-safety authorities.Evidence A · P1
  270. MWITA-FF-2026-023FAO's 2025 global-dialogue report documents an October 2024 stakeholder roundtable on cell-based food and precision-fermentation safety.Evidence A · P1
  271. MWITA-FF-2026-024EFSA concluded in 2025 that Rhizomucor pusillus biomass powder was safe under the proposed conditions of use.Evidence A · P1
  272. MWITA-FF-2026-025EFSA's panel found no genotoxicity concern and no toxicologically relevant effect at the highest dose in the submitted 90-day study for the fungal biomass.Evidence A · P1
  273. MWITA-FF-2026-026EFSA assessed the likelihood of allergic reactions to the Rhizomucor biomass novel food as low.Evidence A · P1
  274. MWITA-FF-2026-027FDA's GRAS inventory distinguishes notices receiving 'no questions' letters from notices whose evaluation ceased at the notifier's request.Evidence A · P1
  275. MWITA-FF-2026-028An FDA 'no questions' GRAS response addresses a notifier's conclusion for specified uses rather than granting general pre-market approval to a technology platform.Evidence A · P1
  276. MWITA-FF-2026-029A 2025 primary study established a non-adherent insect cell line and tested it in 2.4-litre and 10-litre bioreactors for cultivated-meat research.Evidence A · P1
  277. MWITA-FF-2026-030The insect cell line reached a peak density of about two million cells per millilitre in the 10-litre bioreactor, with slower-than-expected growth.Evidence A · P1
  278. MWITA-FF-2026-031The insect-cell study reported viability above 80 percent during three passages in the 2.4-litre bioreactor.Evidence A · P1
  279. MWITA-FF-2026-032A 2025 lamb-muscle-cell study found one serum-free medium outperformed fetal-bovine-serum medium on cell density and modeled cost per million cells in two-dimensional culture.Evidence A · P1
  280. MWITA-FF-2026-033In three-dimensional microcarrier culture, the same serum-free formulations cost 4.5 to 5.6 times more per million cells than the fetal-bovine-serum comparator.Evidence A · P1
  281. MWITA-FF-2026-034The lamb-cell results show that media performance observed in two-dimensional culture did not transfer directly to production-relevant three-dimensional culture.Evidence A · P1
  282. MWITA-FF-2026-041Solar Foods reported that Factory 01 reached its design capacity of 160 tonnes of Solein per year during 2025.Evidence A · P1
  283. MWITA-FF-2026-042Solar Foods reported multiple Solein-based consumer-product launches in Singapore during 2025.Evidence A · P1
  284. MWITA-FF-2026-043Solar Foods reported four LOIs or MOUs covering 6.5–7.65 kilotonnes of prospective annual volume, alongside a planned 6.4-kilotonne Factory 02.Evidence A · P1
  285. MWITA-BT-2026-024At announcement, L’Oréal scheduled Cell BioPrint for a pilot with one of its brands in Asia later in 2025.Evidence C · P1
  286. MWITA-BT-2026-025TikTok reported that 20 million businesses were actively selling on TikTok Shop in Southeast Asia in 2025.Evidence C · P1
  287. MWITA-BT-2026-026TikTok reported four million creators actively selling on TikTok Shop in Southeast Asia in 2025.Evidence C · P1
  288. MWITA-ER-2026-023The same Chinese government portal reported more than ten Keenon medical-service robots operating in a Shanghai hospital.Evidence A · P1
  289. MWITA-ER-2026-037ISO 10218-1:2025 excludes service, consumer and medical robots and public-access applications from its scope.Evidence A · P1
  290. MWITA-BMF-2026-001India reported establishing a national network of six biofoundries under the BioE3 policy by December 2025.Evidence A · P1
  291. MWITA-BMF-2026-002India reported establishing 15 shared biomanufacturing hubs for pilot and pre-commercial scale work under BioE3.Evidence A · P1
  292. MWITA-BMF-2026-003India's BioE3 implementation covers six verticals: bio-based chemicals and enzymes, smart proteins, precision biotherapeutics, climate-resilient agriculture, carbon capture and utilization, and marine and space research.Evidence A · P1
  293. MWITA-BMF-2026-005By July 2026, India had issued 11 BioE3 proposal calls and recommended more than 270 projects for funding across discovery and scale-up categories.Evidence A · P1
  294. MWITA-BMF-2026-006India reported receiving more than 450 proposals for shared biofoundry and biomanufacturing-hub infrastructure, with 17 facilities supported under the first call.Evidence A · P1
  295. MWITA-BMF-2026-007India received 284 letters of intent for Bio-AI hubs and recommended 15 hubs for support by July 2026.Evidence A · P1
  296. MWITA-BMF-2026-008India established a BioE3 Strain Resource Centre to provide indigenous microbial strains with stated freedom-to-operate for commercial use.Evidence A · P1
  297. MWITA-BMF-2026-009Singapore's A*STAR fermentation joint lab operates two food-grade 100-litre bioreactors and a 15-litre-per-hour spray dryer.Evidence A · P1
  298. MWITA-BMF-2026-010The A*STAR joint lab states that processes can transfer from its 100-litre capability to ScaleUp Bio's 10,000-litre fermentation capacity in Tuas.Evidence A · P1
  299. MWITA-BMF-2026-011The Singapore facility integrates fermentation with downstream operations including spray drying, cross-flow filtration and analytical testing.Evidence A · P1
  300. MWITA-BMF-2026-013Singapore's novel-food definition includes substances produced from microbial cell culture and foods made by a process without significant prior food use for at least 20 years.Evidence A · P1
  301. MWITA-BMF-2026-014Singapore can cancel a novel-food pre-market approval after material manufacturing changes, non-compliance, misrepresentation or a public-interest determination.Evidence A · P1
  302. MWITA-BMF-2026-015Singapore's Food Agency committed SGD 42 million in 2025 to future-food and food-safety research.Evidence A · P1
  303. MWITA-BMF-2026-016Singapore awarded additional funding to the Centre for Precision Fermentation and Sustainability to translate research toward market-ready solutions.Evidence A · P1
  304. MWITA-BMF-2026-017Shanghai's 2023–2025 synthetic-biology action plan explicitly targeted fermentation process scaling and optimization as a common industrial technology.Evidence A · P1
  305. MWITA-BMF-2026-019Japan's METI reported approximately JPY 450 billion in support for R&D and demonstrations through its biomanufacturing-revolution and Green Innovation Fund programs.Evidence A · P1
  306. MWITA-BMF-2026-020METI identified separation, purification and processing as parts of the biomanufacturing value chain in which Japanese manufacturing capabilities may be relevant.Evidence A · P1
  307. MWITA-BMF-2026-021METI described the biomanufacturing market as immature despite public support and technical strengths.Evidence A · P1
  308. MWITA-BMF-2026-022Brazil's G20 bioeconomy report identified bioindustry and industrial biomanufacturing as elements of its bioeconomy agenda.Evidence A · P1
  309. MWITA-BMF-2026-031FDA's recently published GRAS inventory records a no-questions letter for zeaxanthin produced by fermentation with Yarrowia lipolytica CGMCC 39021.Evidence A · P1
  310. MWITA-BMF-2026-032FDA's inventory records a no-questions letter for mycelial biomass of Fusarium compactum CGMCC 41312 used as fungal protein.Evidence A · P1
  311. MWITA-BMF-2026-035Solar Foods reported Factory 01 process productivity of 1 gram per litre per hour and an O2-to-CO2 energy-efficiency value of 2.7.Evidence A · P1
  312. MWITA-BMF-2026-036Solar Foods reported four non-binding letters or memoranda covering 6.5–7.65 kilotonnes of potential annual Solein volume.Evidence A · P1
  313. MWITA-BMF-2026-037Solar Foods selected a site for Factory 02 and continued pre-engineering in 2025, while the final investment decision remained future work.Evidence A · P1
  314. MWITA-BMF-2026-038A 2025 industrial-fermentation techno-economic study modelled scenarios delivering 80,000 kilograms of pure formate dehydrogenase per year.Evidence A · P1
  315. MWITA-BMF-2026-039In the study's empirical low-density scenario, 1-litre fermentation produced 4.2 grams per litre biomass with target protein at 0.1% of cell mass, yielding an estimated levelized pure-protein cost near USD 99,000 per kilogram.Evidence A · P1
  316. MWITA-BMF-2026-040The same study found that large-scale handling of low-density biomass and downstream purification could overwhelm expected economies of scale.Evidence A · P1
  317. MWITA-BMF-2026-045The US Department of Energy's 2026 biotechnology initiative explicitly spans discovery through biomanufacturing scale-up for energy, materials, critical minerals, health, agriculture and biosecurity applications.Evidence A · P1
  318. MWITA-LD-2026-001China's 2025 basic public-health programme instructed local services to provide health examinations for people aged 65 and older.Evidence A · P1
  319. MWITA-LD-2026-002China added chest digital radiography and glycated-haemoglobin testing to the specified 2025 examination content for adults aged 65 and older.Evidence A · P1
  320. MWITA-LD-2026-003China's 2025 older-adult examination guidance retained basic vision and hearing assessment.Evidence A · P1
  321. MWITA-LD-2026-004China's 2025 guidance continued initial cognitive-function screening in older-adult public-health services.Evidence A · P1
  322. MWITA-LD-2026-005China issued a national dementia action plan covering 2024–2030 through 15 government bodies.Evidence A · P1
  323. MWITA-LD-2026-006China's dementia plan calls for early screening and intervention alongside diagnosis, treatment, rehabilitation and care services.Evidence A · P1
  324. MWITA-LD-2026-007A 2025 Chinese biological-age study developed models in 83,571 Kailuan participants and validated them in a separate 21,229-person cohort.Evidence A · P1
  325. MWITA-LD-2026-008The Kailuan study recorded 12,679 deaths over 1,443,857 person-years across its two prospective cohorts.Evidence A · P1
  326. MWITA-LD-2026-009Baseline Pheno-Age achieved mortality AUCs of 0.810 in Kailuan I and 0.867 in Kailuan II, while KDM-Age achieved 0.806 and 0.819.Evidence A · P1
  327. MWITA-LD-2026-010Each standard-deviation increase in baseline Pheno-Age acceleration was associated with a 1.24 adjusted mortality hazard ratio, and KDM-Age acceleration with 1.16.Evidence A · P1
  328. MWITA-LD-2026-011China's TALENTs trial randomized 121 adults aged 60–70 to 1.2 grams per day of nucleotides or placebo for 19 weeks.Evidence A · P1
  329. MWITA-LD-2026-012TALENTs reported a 3.08-year greater reduction in median DNA-methylation age versus placebo at 19 weeks.Evidence A · P1
  330. MWITA-LD-2026-013TALENTs found no significant between-group change in leukocyte telomere length at either 11 or 19 weeks.Evidence A · P1
  331. MWITA-LD-2026-014TALENTs reported improved HOMA-IR but no severe adverse events during the 19-week study.Evidence A · P1
  332. MWITA-LD-2026-015India launched a special campaign from 20 February to 31 March 2025 targeting screening of all adults aged 30 and older for diabetes, hypertension, oral, breast and cervical cancers.Evidence A · P1
  333. MWITA-LD-2026-016India's campaign used Ayushman Arogya Mandirs and other facilities, supplemented by home outreach from community health workers.Evidence A · P1
  334. MWITA-LD-2026-017India instructed states and territories to ensure blood-pressure monitors, glucometers and necessary medicines at campaign health centres.Evidence A · P1
  335. MWITA-LD-2026-018Singapore reported more than 1.4 million Healthier SG enrollees by May 2026, equal to 59% of the eligible population.Evidence A · P1
  336. MWITA-LD-2026-019Singapore reported that 83% of Healthier SG enrollees had completed a first Health Plan by May 2026.Evidence A · P1
  337. MWITA-LD-2026-020Of Healthier SG enrollees due for an annual check-in in 2025, 66% completed it that year.Evidence A · P1
  338. MWITA-LD-2026-021Singapore reported more than 1,100 general-practice clinics and polyclinics participating in Healthier SG by June 2026.Evidence A · P1
  339. MWITA-LD-2026-022Singapore's 2026 Screening Test Review Committee updated recommendations for major cancers, diabetes, lipids, hypertension, obesity and osteoporosis after the prior 2019 review.Evidence A · P1
  340. MWITA-LD-2026-023Singapore's committee recommends risk-personalized screening in primary care with explanation and follow-up rather than undifferentiated mass-screening events.Evidence A · P1
  341. MWITA-LD-2026-024Singapore's screening guidance treats interpretation and follow-through as part of effective preventive screening, not as optional services after testing.Evidence A · P1
  342. MWITA-LD-2026-025The ABIOS study is a single-centre, cross-sectional observational study of community-dwelling Chinese, Malay and Indian adults in Singapore.Evidence A · P1
  343. MWITA-LD-2026-026ABIOS collects molecular, physiological and digital ageing measures, including methylation, proteomics, body composition, arterial stiffness, cognition, physical performance, activity and facial morphology.Evidence A · P1
  344. MWITA-LD-2026-027ABIOS explicitly notes that direct comparison with Caucasian populations is outside its current protocol.Evidence A · P1
  345. MWITA-LD-2026-028South Korea's public dementia pathway uses the Cognitive Impairment Screening Test at dementia relief centres as an initial screening step.Evidence A · P1
  346. MWITA-LD-2026-029Japan adopted the Questionnaire for Medical Checkup of Old-Old People after 2020 to assess frailty, falls, fractures, dementia and other geriatric risks in adults aged 75 and older.Evidence A · P1
  347. MWITA-LD-2026-030A Japanese validation study linked the older-adult questionnaire with health-insurance claims and annual-checkup data to develop a functional-disability risk score.Evidence A · P1
  348. MWITA-LD-2026-032FDA evaluated the Lumipulse plasma ratio in 499 cognitively impaired adults against amyloid PET or cerebrospinal-fluid results.Evidence A · P1
  349. MWITA-LD-2026-033In FDA's reviewed study, 91.7% of positive results had amyloid pathology and 97.3% of negative results lacked it, while fewer than 20% of results were indeterminate.Evidence A · P1
  350. MWITA-LD-2026-034FDA warns that false Lumipulse results can cause inappropriate diagnosis or treatment, distress, unnecessary testing or delayed effective treatment.Evidence A · P1
  351. MWITA-LD-2026-035NCI's Vanguard pilot plans to enroll up to 24,000 cancer-free adults aged 45–75 to study two multi-cancer blood tests.Evidence A · P1
  352. MWITA-LD-2026-036Vanguard randomly assigns participants to one of two multi-cancer detection tests or a no-test group while encouraging standard screening in all groups.Evidence A · P1
  353. MWITA-LD-2026-037NCI states that multi-cancer detection tests can return false positives and false negatives and require further testing after a positive result.Evidence A · P1
  354. MWITA-LD-2026-038WHO defines healthy ageing as developing and maintaining the functional ability that enables well-being in older age.Evidence A · P1
  355. MWITA-LD-2026-039WHO's healthy-ageing framework combines intrinsic physical and mental capacity with environmental conditions and their interaction.Evidence A · P1
  356. MWITA-LD-2026-040A 2025 post-hoc DO-HEALTH analysis evaluated four DNA-methylation ageing measures in 777 older adults over three years.Evidence A · P1
  357. MWITA-LD-2026-041DO-HEALTH reported omega-3 effects on three methylation clocks and additive effects of omega-3, vitamin D and exercise on PhenoAge, but the analysis did not demonstrate extended survival.Evidence A · P1
  358. MWITA-LD-2026-042The PBAR pilot randomized 120 healthy older adults to supplement combinations or placebo and used an NT-proBNP-derived biological-age surrogate as its primary outcome.Evidence A · P1
  359. MWITA-LD-2026-043PBAR stopped its resveratrol-plus-TA-65 arm at month five after a significant LDL-cholesterol increase, while the remaining active and placebo groups had non-significant primary and secondary differences.Evidence A · P1
  360. MWITA-LD-2026-044FDA states that many direct-to-consumer tests offered for non-medical general wellness or low-risk medical purposes are not reviewed before sale.Evidence A · P1
  361. MWITA-LD-2026-045FDA cautions that a positive direct-to-consumer genetic health-risk result does not mean the person will develop the disease or condition.Evidence A · P1
  362. MWITA-NA-2026-002The same Chinese opinion explicitly couples industrial development with safety and includes health, rehabilitation and industrial applications in its stated scope.Evidence A · P0
  363. MWITA-NA-2026-007A registered Chinese study recruited 30 children aged four to six with cerebral palsy; 20 completed the MI-BCI lower-limb robot experiment with usable EEG data.Evidence B · P0
  364. MWITA-NA-2026-008The pediatric experiment was ethics-approved and registered as ChiCTR2400080145.Evidence B · P0
  365. MWITA-NA-2026-011Japan's official clinical portal lists a recruiting study of BMI treatment for post-stroke upper-limb paralysis.Evidence A · P0
  366. MWITA-NA-2026-012The Japanese record was last updated on 31 August 2026, one day before this wave's research cutoff.Evidence A · P0
  367. MWITA-NA-2026-019India's Department of Biotechnology issued a call seeking research on neural mechanisms, neurotool interfaces and resulting proofs of concept.Evidence A · P0
  368. MWITA-NA-2026-020The call preferred investigators with a track record in neural mechanisms or technology development and transfer.Evidence A · P0
  369. MWITA-NA-2026-023Abu Dhabi's health research registry lists UAE-PRIME1 as an early-feasibility study of a robotically implanted BCI for external-device control.Evidence A · P0
  370. MWITA-NA-2026-024The registry categorizes UAE-PRIME1 as research carrying significant or potential risk to human subjects.Evidence A · P0
  371. MWITA-NA-2026-025Brazil's trial registry describes a planned randomized four-arm study of 40 chronic post-stroke participants combining BCI-guided robotics, functional electrical stimulation and active or sham neuromodulation.Evidence A · P0
  372. MWITA-NA-2026-026The Brazilian protocol aims to compare decoding stability during simultaneous stimulation against conventional BCI operation and schedules 20 sessions over four weeks.Evidence A · P0
  373. MWITA-NA-2026-035The OECD Council's 2019 Recommendation sets nine responsible-innovation principles spanning safety, inclusivity, collaboration, deliberation, oversight, personal brain data, stewardship and misuse monitoring.Evidence A · P0
  374. MWITA-NA-2026-041The sponsor-entered PRIME registry record describes a first-in-human early-feasibility study of Neuralink's skull-mounted wireless N1 implant and R1 implantation robot for external-device control.Evidence C · P1
  375. MWITA-NA-2026-042As last updated 9 January 2026, PRIME listed estimated enrollment of 15, estimated primary completion in June 2026 and estimated study completion in January 2031, with no results posted.Evidence C · P1
  376. MWITA-NA-2026-045A 2026 Nature Medicine study reports one man with ALS using an intracortical speech-and-cursor BCI independently at home for more than 3,800 hours over nearly two years, including for full-time employment.Evidence B · P0
  377. MWITA-NA-2026-046The participant generated 183,060 sentences and labeled 92% as at least mostly correctly decoded; formal prompted-word testing reported greater than 99% word accuracy.Evidence B · P0
  378. MWITA-MO-2026-006Adding non-invasive BCI therapy to standard rehabilitation increased one-month FMA-UE improvement by 3.35 points versus standard rehabilitation alone after ischemic stroke.Evidence A · P1
  379. MWITA-MO-2026-007A four-week closed-loop EEG motor-imagery BCI with a rehabilitation glove produced higher upper-extremity and activities-of-daily-living scores than dose- and device-matched non-contingent training in a pilot trial.Evidence A · P1
  380. MWITA-MO-2026-008In a small randomized trial, BCI-controlled ankle-robotics training improved lower-extremity Fugl-Meyer scores and calf spasticity more than ankle robotics without BCI.Evidence B · P1
  381. MWITA-MO-2026-009A participant- and assessor-blinded trial found greater neurophysiological responsiveness with fNIRS-guided BCI than sham feedback but no additional upper-extremity clinical improvement.Evidence A · P1
  382. MWITA-MO-2026-010A pilot trial of BCI-controlled exoskeleton training reported some within-group motor and psychological gains but no significant between-group superiority for walking speed or endurance over exoskeleton training alone.Evidence B · P1
  383. MWITA-MO-2026-011Four weeks of 360-degree immersive mirror therapy improved upper-extremity function more than traditional mirror therapy and conventional physiotherapy in a small three-arm stroke trial.Evidence B · P1
  384. MWITA-MO-2026-012Additional fully immersive VR balance training improved selected mobility and gait measures but not Berg Balance Scale scores versus standard physiotherapy alone in a pilot trial.Evidence B · P1
  385. MWITA-MO-2026-013An eight-week Kinect mixed-reality program improved selected shoulder movement more than home stretching in breast-cancer survivors, while an additional quality-of-life effect was not statistically clear.Evidence B · P1
  386. MWITA-MO-2026-014Wearable-sensor cognitive-motor training produced a small six-minute-walk advantage over seated tablet training but no statistically clear MoCA advantage in older adults.Evidence B · P1
  387. MWITA-MO-2026-015Wearable-based perioperative telemonitoring with nurse response accelerated step-count recovery after cancer surgery by about 6%, statistically significant but below the trial's prespecified 14% clinically relevant target.Evidence A · P1
  388. MWITA-SSCO-2026-004Human and virtual influencers activated different persuasion pathways in Spain, with the human advantage in parasocial relationship larger for hedonic than utilitarian products.Evidence A · P1
  389. MWITA-HCO-2026-001In a preregistered cervical-screening messaging experiment, AI-targeted and AI-tailored narratives were perceived as lower quality and less believable and did not increase screening motivation beyond nonnarrative or generic narratives.Evidence A · P1
  390. MWITA-HCO-2026-002A clinician-validated AI avatar increased immediate semaglutide self-injection knowledge relative to nurse education but produced lower satisfaction and trust, with no significant self-efficacy difference.Evidence A · P1
  391. MWITA-HCO-2026-003Brief GPT-4o conversations increased immediate parental HPV-vaccination intent versus no message but did not outperform country-matched public-health materials, did not persist at 45 days, and did not increase self-reported vaccination uptake.Evidence A · P1
  392. MWITA-HCO-2026-004Labeling otherwise identical physicians as using AI for diagnosis substantially reduced US respondents’ trust and stated intention to seek care, with the lowest ratings under extensive AI use.Evidence A · P1
  393. MWITA-HCO-2026-005ChatGPT-assisted counseling before chemotherapy reduced measured anxiety and depression relative to clinician-led education in a two-center randomized trial, while 11.5% of reviewed AI responses were not rated appropriate.Evidence A · P1
  394. MWITA-HCO-2026-006A five-week motivational-interviewing AI vaccine assistant improved vaccine readiness and health literacy among vaccine-hesitant Hong Kong adults but did not produce a significant group-by-time reduction in vaccine hesitancy.Evidence A · P1
  395. MWITA-HCO-2026-007Adding a clinician-validated cataract chatbot to brochures did not improve knowledge gain, anxiety, or satisfaction, despite high usability among users and a 52% non-engagement rate in the chatbot arm.Evidence A · P1
  396. MWITA-HCO-2026-008Plausible AI misinformation cut novice medical students’ diagnostic accuracy from 21.0% to 9.2%, whereas correct AI explanations did not significantly improve accuracy over no explanation.Evidence A · P1
  397. MWITA-HCO-2026-009A minimal prompting boost improved the evidence-based quality of screening information produced by three LLMs for lay users, but responses remained below required health-communication standards.Evidence A · P1
  398. MWITA-HCO-2026-010Co-designed animations and images increased knowledge of ChatGPT limitations and selectively reduced intention to use it for higher-risk health questions, while leaving lower-risk use intentions similar to control.Evidence A · P1
  399. MWITA-HCO-2026-011Identical digital medical advice was judged less reliable and empathetic and elicited lower willingness to follow when labeled as AI-generated or human-plus-AI than when labeled human-generated.Evidence A · P1
  400. MWITA-HCO-2026-012In a randomized simulated-consultation crossover study, AMIE exceeded primary-care physicians on diagnostic accuracy and most rated communication dimensions, but the unfamiliar text-only OSCE setting prevents inference to clinical deployment.Evidence A · P1
  401. MWITA-CCO-2026-011Customers evaluated chatbot service less favorably than human service after both positive and negative outcomes, with lower perceived empathy explaining the penalty.Evidence A · P1
  402. MWITA-RCO-2026-004Showing relevant context about review writers improved customer conversion and repeated use on a relational-service platform.Evidence B · P1
  403. MWITA-CPCO-2026-006A first text reminder with easy scheduling increased first-dose vaccination at UCLA Health by 3.57 percentage points (26% relative) and vaccination anywhere by 2.1 points (SE 0.4; p<0.001); a second reminder among non-schedulers added 1.06 points at UCLA Health.Evidence A · P1
  404. MWITA-CPCO-2026-008One mailed letter increased completed ACA marketplace enrollment from 4.0% to 4.3%, an absolute 0.3-point effect (95% CI 0.2-0.4; p<0.001) and 1,753 marginal enrollments; action-language variants produced the largest pooled increase at 0.5 points.Evidence A · P1
  405. MWITA-CPCO-2026-009Prompting participants to rate the accuracy of one unrelated headline before evaluating COVID-19 headlines nearly tripled truth discernment in subsequent sharing intentions compared with control.Evidence A · P1
  406. MWITA-PKSO-2026-001Front-of-package health warnings reduced realized sugar-sweetened-beverage purchases in a naturalistic convenience-store experiment, while several product-belief outcomes remained unchanged.Evidence A · P1
  407. MWITA-PKSO-2026-002Among five front-of-package systems, nutrient-specific 'high in' warnings most consistently shifted incentivized beverage and snack purchases toward lower targeted nutrients, but effects were outcome-specific rather than universal.Evidence A · P1
  408. MWITA-PKSO-2026-003In a laboratory grocery aisle, two front-of-package nutrition formats produced mostly null changes in the nutrient profile of parent-child food choices, and explanatory signage yielded only narrow improvements.Evidence A · P1
  409. MWITA-PKSO-2026-004Black-octagon nutrient warnings reduced stated purchase choice for three unhealthy mock products more than Nutri-Score or traffic lights, while nutrient claims partially counteracted warning effects.Evidence A · P1
  410. MWITA-PKSO-2026-005Four interpretive front labels each reduced calories in hypothetical beverage and snack selections relative to calorie-only labels, with similar effects across education groups despite differing attention and trust reactions.Evidence A · P1
  411. MWITA-PKSO-2026-007A child-directed fun label changed experienced liking and effort for objectively identical healthy snacks more strongly than a plain or health label.Evidence A · P1
  412. MWITA-PCR-2026-007Debunks from competitors, media or regulators substantially reversed misinformation-driven product avoidance in incentive-compatible choices; for fluoride toothpaste the share choosing the ingredient fell from .67 to .56 after misinformation and recovered to .64 after debunking.Evidence A · P1
  413. MWITA-BAO-2026-001After permanent national-brand deletion, sister brands captured only about 38% of the deleted revenue; average competitor revenue rose 1.73% (private labels 3.45%, sister brands 2.77%, rival national brands 1.36%) while category revenue fell 2.3%, so portfolio recapture and category health are distinct outcomes.Evidence B · P1
  414. MWITA-BAO-2026-002For Aunt Jemima/Pearl Milling pancake mix, removing the character image alone produced a bounded-null willingness-to-pay response, whereas changing the name reduced willingness to pay by more than 30% and simulated choice share by more than 20 percentage points; an explanatory message mitigated much of the loss.Evidence A · P1
  415. MWITA-BAO-2026-003Controlling for feature similarity, subbrand line extensions cannibalized focal-brand sales in detergent (beta=-0.03, p<.05) and toothpaste (beta=-0.01, p<.001), but not coffee (beta=+0.23, p<.001); feature similarity was a consistently negative sales moderator under both subbrand and stand-alone architectures.Evidence B · P1
  416. MWITA-BAO-2026-005U.S. hotel rebranding was associated with an average 6.31% occupancy increase; about 60% of the modeled effect came from the before/after brand identities and 40% from property-by-brand fit, so the label and the asset-brand match should not be collapsed.Evidence B · P1
  417. MWITA-BAO-2026-006In China's automobile market, semantic model names were associated with 7.64% more sales than alphanumeric names, whereas phonosemantic names were associated with 4.92% fewer; domestic, foreign, entry-level and high-end brands showed different naming advantages.Evidence B · P1
  418. MWITA-BAO-2026-007Across 155 extensions, brand extensions generated larger parent-brand spillovers while line extensions generated larger own-extension effects; subbranding reduced line-extension spillover but improved brand-extension market performance, and upward quality differentiation mitigated negative spillover.Evidence B · P1
  419. MWITA-BAO-2026-008Across six real extensions, successful extension trial increased subsequent parent-brand choice especially among prior parent-brand nonusers, while parent-brand experience predicted extension trial but not repeat; trial and repeat therefore require separate portfolio metrics.Evidence B · P1
  420. MWITA-BAO-2026-009Category similarity changed evaluations for family-branded but not subbranded extensions, and parent-brand dilution appeared only after a negative experience with a similar family-branded extension; in Experiment 3, similar versus dissimilar family-brand ratings were 5.1 versus 4.3, while suggestive subbrands were statistically indistinguishable (5.1 versus 5.4, p>.20).Evidence A · P1
  421. MWITA-BAO-2026-010Extension exposure sped correct parent-brand categorization and improved parent recall, especially for nondominant brands, but both recall and recognition improved less than after equally repeated parent-brand advertising.Evidence A · P1
  422. MWITA-BAO-2026-012After three European retailers consolidated category-specific private labels into one umbrella brand, intrinsic brand strength rose and price elasticity fell at all three, but promotion and assortment-size effectiveness also fell; total revenue increased significantly for two focal retailers, not uniformly across every setting.Evidence B · P1
  423. MWITA-BCO-2026-001Among 784 consulting key accounts, digital-event attendance and owned digital-content consumption predicted more sales leads and won opportunities, whereas in-person-event attendance was null; digital-event association with wins was stronger among senior account employees.Evidence B · P1
  424. MWITA-BCO-2026-002Across two Brazilian B2B field experiments, a WhatsApp-based chatbot generated significantly more total and qualified leads than a static landing page, establishing a top-of-funnel effect without evidence here for meetings, opportunities or revenue.Evidence A · P1
  425. MWITA-BCO-2026-003A telephone foot-in-the-door request increased verbal compliance and actual sales-seminar attendance but produced a bounded-null sales effect, so event attendance did not validate pipeline or revenue impact.Evidence A · P1
  426. MWITA-BCO-2026-004At one Chile/Peru B2B consultancy, a 1% increase in social posts predicted 0.294% more LinkedIn engagement but 0.056% fewer website visits, while sales, technical and social posts had no direct sales-revenue effect; sales posts acted only through followers and site visits.Evidence B · P1
  427. MWITA-BCO-2026-005Coordinating seller contacts around each customer's predicted product needs and purchase timing generated more than US$1 million in incremental profit across two B2B field experiments and improved relationship quality, versus independent product-category calling.Evidence A · P1
  428. MWITA-BCO-2026-006In 160 B2B firms publishing social content, perceived thought-leadership capability was positively associated with brand performance, which in turn mediated customer-relationship performance; the study did not observe retention, pipeline or revenue.Evidence B · P1
  429. MWITA-BCO-2026-007Across two Italian salesperson studies, social selling's insight-generation, connecting and engagement dimensions predicted thought leadership and acquisition performance, which mediated reported sales performance; firm content support was an antecedent, not itself a tested revenue intervention.Evidence B · P1
  430. MWITA-BCO-2026-008A two-stage cluster-plus-score model increased average observed lead conversion from 6.2% under the traditional method to 8.9% without using later behavioral features, a 43.5% relative uplift at lead creation.Evidence B · P1
  431. MWITA-BCO-2026-009Among 171 B2B salespeople, social-media use was positively related to value-oriented prospecting and proactive servicing but not adaptive selling; all three selling tasks related positively to salesperson performance, making the direct tool-to-performance story incomplete.Evidence B · P1
  432. MWITA-BCO-2026-010Social-media-enabled small talk predicted competitive-intelligence sharing and then creative/sales performance for service and mixed-offering sellers, but the pathway was bounded null for product-only sellers.Evidence B · P1
  433. MWITA-BCO-2026-011A model-based account call-frequency planning aid increased six-month sales by 8.1% versus matched manual planning among United Airlines sales representatives.Evidence A · P1
  434. MWITA-BCO-2026-012Randomized digital display advertising by a semiconductor/electronics-components manufacturer produced an estimated return on ad spend of 12.0 (95% CI 4.8-24.5), with first-time purchase effects delayed one to five months and repeat-customer effects delayed five to twelve-plus months.Evidence A · P1
  435. MWITA-XMO-2026-001For one 77-day US campaign targeting men 18-49, reallocating 17.25% of a $40m TV budget to YouTube was modeled to raise 3+ combined reach from 63.72% to 67.51% (+3.79 pp) at fixed cost; a separate solution held 63.72% reach while cutting total cost 18.08%.Evidence B · P1
  436. MWITA-XMO-2026-002Across 26,222 campaign-by-demographic optimization cases derived from 2,914 quarterly US TV campaigns and nine demographic groups, 29.25% were modeled to benefit from shifting TV budget to YouTube; among selected cases, the average optimal shift was about 50% and mean modeled reach gain was 7 percentage points.Evidence B · P1
  437. MWITA-XMO-2026-003For an Android campaign from 1-28 March 2016, 85m TV impressions across 11 networks and 13m YouTube impressions were linked to incremental Google searches; YouTube ranked fifth by cost efficiency and third by impression efficiency among the TV-network comparisons.Evidence B · P1
  438. MWITA-XMO-2026-004The method randomizes eligible users to normal campaign delivery or ad holdout and estimates brand lift as the favorable-response-rate difference; its quantitative comparisons find regression correction more stable than propensity weighting under imperfect solicitation and response.Evidence A · P1
  439. MWITA-XMO-2026-005Immediately after TV spots, online sessions rose significantly but sales evidence was smaller and less stable: treated-region 30-minute means moved from 21.5 to 22.1 sessions (+3%) and $721 to $773 sales (+7%, not significant).Evidence B · P1
  440. MWITA-XMO-2026-006For 10 established CPG brands in two categories, online added mostly duplicated reach to TV; one TV exposure often increased sales, online-only effects were less consistent, and mixed TV-plus-online exposure showed no sales synergy.Evidence B · P1
  441. MWITA-XMO-2026-007Paired TV, web and mobile-TV repetition produced higher credibility, cognitive response, brand attitude and purchase intention than same-device repetition; for high-involvement message credibility, means were 2.63 single-device, 3.11 multi-device and 2.96 reversed multi-device, F(2,279)=10.43, p<.001.Evidence A · P1
  442. MWITA-XMO-2026-008In experiment 1, 30 billboards delivering an estimated 43 daily GRPs for four weeks coincided with a 57.9% year-over-year rise in average daily paid attendance during the campaign, versus -51.1% at a comparison attraction; location, media weight and promotion were significant.Evidence B · P1
  443. MWITA-XMO-2026-009Among almost 35m Pandora listeners, each additional audio ad per hour reduced final-month listening by about 2%; long-run ad-load sensitivity was roughly three times the one-month estimate, while higher load increased paid ad-free subscriptions.Evidence A · P1
  444. MWITA-XMO-2026-010A 400-person panel split evenly into unexposed, CTV-only, DOOH-only and combined CTV+DOOH cells found significant positive relationships for most prespecified attitude-to-media hypotheses, but evidence of CTV-DOOH synergy was inconclusive.Evidence A · P1
  445. MWITA-XMO-2026-011Across 7,500 respondents and 150 tests, sequenced creative outperformed repeating a source 30-second ad on aggregate funnel KPIs; the Direct Shot sequence raised key-message retention by 91%, from 10% to 19%.Evidence A · P1
  446. MWITA-XMO-2026-012Across four experiments, holding format constant produced no device effect on awareness, liking, brand attitude or purchase intent; only the fourth experiment, which changed both format and device, produced sequence-dependent synergy.Evidence A · P1